In September 2019, a small molecule oral anti-tumor drug JAB-3312, which was independently developed by Jacobio with global intellectual property rights, obtained clinical permission in China, and the clinical trials will soon be conducted concurrently in China and the United States. It is also the second drug that has obtained clinical permission both in China and the United States at the same time by Jacobio after JAB-3068.
JAB-3312 will be used to treat solid tumor patients with abnormal genotypes such as KRAS G12 mutation, BRAF Class3, NF1 LoF, and RTK mutation, amplification or rearrangement, including but not limited to non-small cell lung cancer, colorectal cancer, pancreatic cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma. At the same time, JAB-3312 monotherapy or JAB-3312 combined with PD-1 antibody can also be used for patients with non-small cell lung cancer, colorectal cancer, bladder cancer, triple-negative breast cancer, etc, who failed in or were resistant to the treatment of PD-1/PD-L1 antibody.
Following the entry of JAB-3068 into clinical phase IIa, the initiation of JAB-3312 clinical trial will provide patients with additional treatment options.
Jacobio Pharmaceuticals Co., Ltd., headquartered in Beijing, focuses on the R&D of innovative medicines, It dedicates to provide breakthrough innovations to treat major diseases and bring more solutions to promote human health. The vision of Jacobio is to become a global leader in pharmaceutical industry. Jacobio has established an R&D center in Boston, USA, to strengthen and coordinate the global development of new drugs.